While the unprecedented number of major drugs losing patent protection in 2011 and 2012 has cast a gloomy shadow, the industry has quietly had one of its best years for launching novel therapies. Scr
Perhaps because the ideal analgesic has yet to be discovered, there is intense clinical trial activity in the pain area. Furthermore, there is a good chance that the next few years will witness at lea
As Big Pharma continues to digest its latest round of mega-mergers, and as biotechs, by and large, enjoy record stock market valuations, we wondered how all this has been affecting trends in up-front